PreciseDx Raises $20.7M for AI-Powered Cancer Risk Assessments
What You Should Know:
– PreciseDx, a pioneering company in oncology diagnostics utilizing artificial intelligence (AI) raises $20.7M in Series B funding led by Eventide Asset Management with participation from Labcorp, Quest Diagnostics, GenHenn Capital…
Continue Reading